Knatterud G L, Bourassa M G, Pepine C J, Geller N L, Sopko G, Chaitman B R, Pratt C, Stone P H, Davies R F, Rogers W J
University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville 32610-0277.
J Am Coll Cardiol. 1994 Jul;24(1):11-20. doi: 10.1016/0735-1097(94)90535-5.
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study was initiated to determine the feasibility of a large trial in evaluating the effects of treatment of ischemia on outcome (mortality and myocardial infarction). The study was designed to examine the effects of medical treatment to control angina compared with treatment strategies guided by ambulatory electrocardiographic (ECG) ischemia or coronary anatomy.
Treatments to suppress ischemia (asymptomatic and symptomatic) have not been evaluated in a large prospective, randomized trial. Before undertaking such a trial, issues about recruitment and treatment strategies must be addressed.
The 618 enrolled patients had coronary artery disease suitable for revascularization, ischemia on stress test and asymptomatic ischemia on ambulatory ECG. Patients were assigned randomly to one of three treatment strategies: 1) angina-guided medical strategy with titration of anti-ischemic medication to relieve angina (angina-guided strategy); 2) angina-guided plus ambulatory ECG ischemia-guided medical strategy with titration of anti-ischemic medication to eliminate both angina and ambulatory ECG ischemia (ischemia-guided strategy); and 3) revascularization by angioplasty or bypass surgery (revascularization strategy).
Ambulatory ECG ischemia was no longer present at the week 12 visit in 39% of patients assigned to the angina-guided strategy, 41% of patients assigned to the ischemia-guided strategy and 55% of patients assigned to the revascularization strategy. All strategies reduced the median number of episodes and total duration of ST segment depression during follow-up ambulatory ECG monitoring. Revascularization was the most effective strategy. Treadmill test results were concordant with those of ambulatory ECG monitoring. For most patients in the two medical strategies, angina was controlled with low to moderate doses of anti-ischemic medication, and the majority of patients (65%) in the revascularization strategy did not require medication for angina.
This pilot study demonstrated that cardiac ischemia can be suppressed in 40% to 55% of patients with either low or moderate doses of medication or revascularization and that a large trial is feasible.
启动无症状性心肌缺血试点(ACIP)研究,以确定进行一项大型试验来评估缺血治疗对预后(死亡率和心肌梗死)影响的可行性。该研究旨在比较药物治疗控制心绞痛与动态心电图(ECG)缺血或冠状动脉解剖指导下的治疗策略的效果。
在一项大型前瞻性随机试验中,尚未对抑制缺血(无症状和有症状)的治疗方法进行评估。在开展此类试验之前,必须解决招募和治疗策略等问题。
618名入选患者患有适合血运重建的冠状动脉疾病、运动试验显示缺血且动态心电图显示无症状性缺血。患者被随机分配至三种治疗策略之一:1)心绞痛指导的药物策略,通过调整抗缺血药物剂量以缓解心绞痛(心绞痛指导策略);2)心绞痛指导加动态心电图缺血指导的药物策略,通过调整抗缺血药物剂量以消除心绞痛和动态心电图缺血(缺血指导策略);3)通过血管成形术或搭桥手术进行血运重建(血运重建策略)。
在第12周随访时,分配至心绞痛指导策略的患者中39%、分配至缺血指导策略的患者中41%以及分配至血运重建策略的患者中55%的动态心电图缺血不再存在。所有策略均减少了随访期间动态心电图监测时ST段压低的发作中位数和总持续时间。血运重建是最有效的策略。平板运动试验结果与动态心电图监测结果一致。对于两种药物策略中的大多数患者,低至中等剂量的抗缺血药物可控制心绞痛,而血运重建策略中的大多数患者(65%)无需使用治疗心绞痛的药物。
这项试点研究表明,40%至55%的患者可通过低剂量或中等剂量药物治疗或血运重建来抑制心肌缺血,且进行一项大型试验是可行的。